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provide PE education, however the number of hours is sufficiently greater for
schools with an elective (variable) course in PE. In addition, results pertaining to the
opinions of key educators on the insufficiency of number of hours devoted to
PE-related topics and on enhancing PE education should be noted.
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OBJECTIVES: Early Access Programmes (EAPs) provide the possibility of making
medicines that address an unmet medical need available to patients before regu-
latory approval of the European Medicine Agency. Market Access includes market
development activities and patient access strategy, EAPs can positively impact
both areas. The aim of this review is to consider, compile and describe the main
EAPs available in Europe. METHODS: We conducted a review and performed a
mapping of EAPs systems that exists in Europe. We searched existing literature in
Embase, National Health Systems Website, ISPOR conference websites and Inter-
net. In the countries where information were more scattered we directly contacted
regulatory agencies and clinicians familiar with the local EAP regulations and
practices. RESULTS: We described the practical implications surrounding the reg-
ulatory framework for EAPs, the key stakeholders involved in EAP decision-making
and administration, the timelines for EAPs approval, and the key factors for suc-
cess. Many countries do not have an EAP in place and compassionate use is the only
route to market for unregistered or investigational products. This is the case for
Germany, Belgium, Poland, Austria and Switzerland. The markets where EAP are
more developed and sales are possible are: France, Spain, UK, Italy, Sweden, Den-
mark, Portugal, and Norway. CONCLUSIONS: This project made specific recom-
mendations on the most favourable countries, based on the ease of setting up such
a programme and the potential revenue that could result. At the time, there were
several countries where the legal framework was changing (e.g. Austria) and some
markets where information was simply not available.
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OBJECTIVES: Since January 2011 the new German AMNOG health care reform in-
cludes a mandatory EBA for innovative medicines. At time of launch pharmaceu-
tical companies have to submit a benefit dossier which is subsequently evaluated
by the Institute for Quality and Efficiency in Health Care (IQWiG). Our aim was to
explore differences in companies’ benefit claims and the respective IQWiG
assessments. METHODS: The review includes EBAs that were started in 2011. The
Joint Federal Committee’s (GBA) webpage was used to obtain the respective com-
panies’ benefit claims and IQWiG overall (i.e. aggregated, not on endpoint level)
benefit assessments. The GBA’s official scale is discriminating six levels of addi-
tional benefit versus comparative treatment: 1: major; 2: significant; 3: marginal; 4:
not quantifiable; 5: no benefit; 6: less benefit. IQWiG’s official evidence categories
include: 1: proof; 2: indication; 3: hint. For the purpose of this abstract always the
highest benefit level and evidence category claimed/assessed was taken into
account. RESULTS: Twenty-four EBAs were started in 2011: Tafamidis Meglumin,
Telaprevir, Abirateronacetat, Linagliptin, Pirfenidon, Boceprevir, Bromfenac, Ipili-
mumab, Fampridin, Belimumab, Belatacept, Dexmedetomidin, Cannabis Sativa,
Apixaban, Pitavastatin, Retigabin, Aliskiren/Amlodipin, Collagenase, Eribulin,
Cabazitaxel, Fingolimod, Regadenoson, Ticacrelor, Olmesartan/Amlodipin/Hydro-
chlorthiazid. The companies’ benefit claims/IQWiG benefit assessments included
the benefit level: major in 11/0 EBAs; significant 4/4; marginal 0/3; not quantifiable
1/2; no benefit 1/8; less benefit 0/0. Two Orphan indications were excluded from
this analysis; for five drugs no full dossier submissions and/or IQWiG assessments
were conducted (Bromfenac; Dexmedetomidin; Pitavastatin; Regadenoson; Olm-
esartan/Amlodipin/Hydrochlorthiazid) which resulted in a ‘no benefit’ conclusion
by the GBA. Companies claimed a proof in thirteen EBAs. IQWiG acknowledged a
proof in three EBAs. CONCLUSIONS: Both, evidence and benefit levels show major
differences between companies’ claims and IQWiG assessments. Most frequently
companies claimed a major benefit (11 EBAs) while IQWiG most frequently applied
the ‘no benefit’ category (8 EBAs).
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OBJECTIVES: Screening technologies are on the forefront of innovation and have
an impact on the care of patients in terms of identifying disease and appropriate
treatment options at an early stage. As such, screening technologies are of key
interest to health technology assessment (HTA) agencies in the United States (US)
and abroad. The objective of this research study is to evaluate existing technology
assessment standards for screening technologies in order to establish a best prac-
tice that may be implemented by US technology assessment organizations to
broaden the criteria used in assessments for screening products. METHODS: Qual-
itative interviews involving 12 HTA experts from the US, Canada, and the UK were
conducted. The experts represented HTA organizations that were for profit, not for
profit, government agencies, private payers, and academic medical centers. While
quantitative analysis of the levels of evidence required by HTA organizations for
screening products would produce a desirable study design, the findings from the
literature review indicated that quantitative evidence does not exist.RESULTS:The
results of this study indicate that the best practices should include criteria to sup-
port screening reliability, sensitivity and specificity; evaluate data to identify ap-
propriate patient populations; reference to the natural course of the disease; con-
sider ethical implications; and the impact of cost. CONCLUSIONS: HTA criteria
specific to the evaluation of screening products would positively impact HTA stake-
holders such as HTA organizations, their clients, patients, as well as technology
innovators. Best practices designed to help HTA organizations choose criteria that
are focused on screening technologies will help to identify whether relevant pa-
tient populations for the technology exist. In so doing, levels of evidence and data
requirements would be more transparent to screening technology innovators and
patients. Cost should be a part of the assessment to understand the cost and benefit
of using the product in specific patient populations for appropriate clinical decision
making.
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OBJECTIVES: Estimating the critical threshold value from previous reimbursement
decisions is one of the several methods to determine a cost effectiveness threshold.
The methodology is based on analyzing the relationship between the Incremental
Cost Effectiveness Ratio (ICER) of the assessed health technologies, and the reim-
bursement decisions. Our study tries to examine if there is any relationship be-
tween cost effectiveness and decision making in Hungary by analyzing data ab-
stracted from HTA appraisals and health economic studies. METHODS: The
members of the HTA Department examined the submissions containing a cost-
utility analysis which were assessed by the Hungarian HTA Office since 2004. We
created a database in which we summed up the cost/QALY values of the examined
submissions and HTA reports. We analyzed the appraisal determinations of the
HTA Committee regarding the assessed submissions in order to examine the like-
lihood of a positive/negative decision according the level of the assessed pharma-
ceutical’s ICER value. We searched for the technology with the highest ICER value,
which got reimbursed. RESULTS: We examined 165 submissions which contained
a cost-utility analysis that have arrived to our Department. Our results suggest that
there is only a weak correlation (r0,14) between the level of the calculated ICER
and the reimbursement decisions. We found, that the highest ICER which resulted
a positive reimbursement decision was 9 500 000 HUF/QALY (32 000 EUR).
CONCLUSIONS: One of the several methods to determine a threshold value is to
examine the relationship between previous reimbursement decisions and ICER
values calculated in health economic appraisals. However one must take into ac-
count, that estimating a threshold value based on prior decisions has limitations,
as reimbursement decisions are almost never made based on ICER ratios alone.
This could be the main reason our study only showed a weak correlation between
the level of calculated ICERs and the outcomes of the determinations.
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OBJECTIVES: To identify, using HTAinSite, if and how manufacturers have used
improved patient compliance as a value argument for their product in submissions
to the National Institute for Health and Clinical Excellence (NICE). We analysed if
and how compliance data were presented, how they were received by NICE, and if
they were an influential factor in NICE’s decision making.METHODS: A key phrase
search in HTAinSite was used to identify instances of ‘compliance’ and ‘adherence’
in manufacturer submissions and NICE technology appraisal (TA) documents. Af-
ter review for relevance, information was extracted and used to conduct a qualita-
tive analysis. RESULTS: Fifteen manufacturer’s submissions and 12 TAs reported
an improvement in compliance as a value argument for their drug. Factors used to
justify improved compliance included improved convenience, a reduction in ad-
verse events, increased treatment choice, and improved route of administration. In
8 of 13 TAs (relating to 11 manufacturer submissions), NICE state that the compli-
ance argument was considered by the Committee. In the remaining 5 TAs, despite
inclusion of a compliance argument by manufacturers in their submissions, the
Committee made no reference to it in the TA. Interestingly, only three manufac-
turers explicitly reported evidence supporting their compliance argument; how-
ever, the Committee discussed this in all of the associated TAs. The impact of
improved compliance on clinical outcomes or cost-effectiveness was frequently
not clearly reported by manufacturers or NICE. NICE did not explicitly cite compli-
ance as an influential factor in their final decision in any TAs. CONCLUSIONS: The
committee are more likely to consider a compliance argument if there is a clear
clinical rationale and it is accompanied by supporting data. Although compliance
arguments are considered by the Committee, NICE have not explicitly stated to
have used them to influence final decisions.
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THE EARLY BENEFIT ASSESSMENT OF DRUGS THAT ARE LAUNCHED BEFORE
2011
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